CAR-T Cell Therapy for Multiple Myeloma Market
完整報告名稱與涵蓋範圍
CAR-T Cell Therapy for Multiple Myeloma Market Size, Share & Trends Analysis Report By Therapy Type (Bb2121, JNJ-68284528 (LCAR-B38M), P-BCMA-101, CAR-CD44V6, Others), By Region, And Segment Forecasts, 2023-2031.
報告摘要
The CAR-T Cell Therapy for Multiple Myeloma Market is positioned for steady expansion, with a projected CAGR of 27.0% from 2023 to 2031.
CAR-T Cell Therapy for Multiple Myeloma encompasses an innovative treatment that encompasses the reengineering of white blood cells (wbc) of a cancer patient's to fight the malignant cells by identifyin. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CAR T-Cell Therapy for Multiple Myeloma - Market Snapshot
Chapter 4. Global CAR T-Cell Therapy for Multiple Myeloma - Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Clinical Trial/Pipeline Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Technology Advancement/Application Trends in CAR-T Cell Therapy
4.9. Incidence of Multiple Myeloma by Key Countries
4.10. Major Investment, Partnerships and Collaborations
4.11. Impact of COVID 19 on Immuno-oncology Industry
Chapter 5. Market Segmentation 1: Therapy Type Estimates & Trend Analysis
5.1. Therapy Type & Market Share, 2020 & 2030
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2027 for the following Therapy Type:
5.2.1. Bb2121
5.2.2. JNJ-68284528 (LCAR-B38M)
5.2.3. P-BCMA-101
5.2.4. CAR-CD44V6
5.2.5. Others
Chapter 6. CAR T-Cell Therapy for Multiple Myeloma - Market Segmentation 3: Country/Region Estimates & Trend Analysis
6.1. The US
6.1.1. The US CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) estimates and forecasts by therapy type, 2020-2030
6.2. Germany
6.2.1. Germany CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) by therapy type, 2020-2030
6.3. France
6.3.1. France CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) by therapy type, 2020-2030
6.4. The UK
6.4.1. The UK CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) by therapy type, (US$ Million) 2020-2030
6.5. Italy
6.5.1. Italy revenue CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) by therapy type, (US$ Million) 2020-2030
6.6. Rest of World
6.6.1. Rest of World revenue CAR T-Cell Therapy for Multiple Myeloma - Market revenue (US$ Million) by therapy type, (US$ Million) 2020-2030
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Bluebird bio/Celgene
7.2.2. Janssen Research & Development
7.2.3. Poseida Therapeutics
7.2.4. MolMed S.p.A.
7.2.5. Celgene Corporation
7.2.6. Cartesian Therapeutics
7.2.7. CARsgen Therapeutics
7.2.8. Precision BioSciences
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們